Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist
Data(s) |
2015
|
---|---|
Resumo |
Androgen deprivation and androgen targeted therapies (ATT) are established treatments for prostate cancer (PCa). Although initially effective, ATT induces an adaptive response that leads to treatment resistance. Increased expression of relaxin-2 (RLN2) is an important alteration in the adaptive response. RLN2 has a well described role in PCa cell proliferation, adhesion and tumour growth. The objectives of this study were to develop cell models for studies of RLN2 signalling and to implement in vitro assays for evaluating the therapeutic properties of the unique RLN2 receptor (RXFP1) antagonist |
Formato |
application/pdf |
Identificador | |
Publicador |
Blackwell Publishing |
Relação |
http://eprints.qut.edu.au/94796/8/94796.pdf http://onlinelibrary.wiley.com/doi/10.1111/bju.2015.116.issue-S1/issuetoc Tevz, Gregor, Hossain, Akther, Bock, Nathalie, Jeet, Varinder, Bathgate, Ross A., Williams, Elizabeth D., Lehman, Melanie, Hutmacher, Dietmar, Wade, John D., & Nelson, Colleen (2015) Impeding the adaptive response of prostate cancer to androgen targeted therapies with relaxin receptor antagonist. In 2nd Prostate Cancer World Congress, 17-21 August 2015, Cairns Convention Centre, Cairns, Qld. |
Direitos |
2015 The Authors |
Fonte |
School of Biomedical Sciences; Faculty of Health; Institute of Health and Biomedical Innovation |
Palavras-Chave | #111201 Cancer Cell Biology #111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) #111207 Molecular Targets #Adaptive response #prostate cancer #androgen-targeted therapies #relaxin #receptor antagonist |
Tipo |
Conference Item |